These factors, coupled with the wide inter-individual variability and ethnic differences that also characterise variable UGT expression in tissues,1 suggest a multifaceted regulation of UGT expression by oncogenic conditions, which, in turn, will significantly influence not only the drug response, but also tumour progression, as described below. Here, SLC35A2 is linked to neoplasm.